George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Average daily volume is 32m and we're going to hit that in the first 75 minutes of trading
And still in goes down. Not mad, just disappointed...
Nope, currently down 2.8% live
Thanks, been working on it all morning
Are buys
What's your break even price Learner?
This uptick after a very gloomy BB of late! GLA and Rufus....when you're ready my son
100% year on year revenue growth: https://www.newcannabisventures.com/aphria-q3-sales-grow-100/
The spread narrowing, might trigger a bit of activity. Just a shame about the price! BOD need to update us on these contracts, the atmosphere here is turning a little sour..
Completely agree Jarv, AIM has become full of short term thinking/expectations of late. I was just trying to highlight that this is not going anywhere fast with my posts. Good luck to you, this should do well over the longer term
Jarv, i’m not misleading anyone. Just adding a bit of balance to all the ‘250p by lunch’ posts. Also, I can confirm I do not work for the MM’s, but do work for a pharma firm and have a specific interest in biotech stocks. Good luck ramping this until you get your exit price, think you might be waiting a while buddy
Sorry, your "No Risk here" comment threw me...
Birdseye, it's not a $284m contract for services. The $284m is contingent upon C4XD's drug passing each phase of a clinical trial. Very few drugs actually manage this. Therefore the risk here is huge and the only real value of this deal right now is $10m, which has to be spent on developing the drug. The remaining $284m is not guaranteed in anyway and will not be payable until the next phase of clinical trials, which is likely to take a minimum of a year
Bottom drawer sounds like a good strategy. The good news is that once you have one licensing deal, it opens the door for more suitors. Hope that next spike up is a good one for you. R
Everyone's been talking about how great a deal this contract is which is fair due to the numbers involved, but no one has talked about the sky high risks involved in achieving those numbers.. Orexin 1 is pre-clinical, so it hasn't been anywhere near a human (the only testing will have been done in a test tube or on a mouse). Over 85% of central nervous drugs fail in clinical trials, and this drug hasn't even reached a clinical trial. What we have seen is Indivior paying $10m to effectively get this drug fully tested in further trials in the clinic. If (and it's a big 'IF') the initial trials are successful, then and only then can the milestone payments be received. Bear in mind that each clinical trial stage takes several years....and that there are 3 of them to get through.....and then you start to realise that as well as the risks of failing a clinical trial, there is also the fact that this drug is at 5-10 years away from launch and the associated milestone payments. People are talking as though the $295m is practically in the bank, but in reality, with a 15% chance of success, the real value is $44m/�31m, which is roughly what we saw added to the market cap in the last 5 days. There are no updates due on the contract, so the price will only drift down. This could be a great investment given their other assets, but again, they are at 'research projects' so they are even earlier in development than Orexin. Hope this helps to bring a bit of balance, GLA
Are actually buys
No specific news expected, this has just been oversold and found the bottom at 8p down from 38p in Jan. I doubt it will hit 38p without news but current volumes and charts are pointing to the low 20's in the short term
Still oversold at this level. �25m revenues and roughly �2m profit. On the move again now
Back into auction. Going to be an interesting one
Mr 2,041,306 lost over £2k in 3 hours